Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education



Front Page

World

UK

UK Politics

Business

Sci/Tech

Health

Education

Sport

Entertainment

Talking Point

In Depth

On Air

Archive
Feedback
Low Graphics
Help

Friday, October 1, 1999 Published at 10:42 GMT 11:42 UK


Health

Tamoxifen works in smaller doses

Tamoxifen is associated with side effects

Women may be able to cut the dose of a cancer-preventing drug by three quarters and still gain the same protection, scientists have discovered.

The findings could mean that patients taking the drug - found to reduce the incidence of breast cancer in women at high risk by more than 40% - avoid some of its side effects.

Dr Andrea Decensi, of the European Institute of Oncology in Milan and colleagues in Norway, gave a group of 105 women varying doses of tamoxifen.

They found that a much smaller dose - one that reduced the amount of tamoxifen in the blood by 80 percent - still seemed to be working.

Tamoxifen, sold under the name Nolvadex, has been used for years to treat breast cancer. But last year it was also found to prevent breast cancer in some women when they took it for five years.

The drug works by blocking the action of the female sex hormone oestrogen on cells.

Oestrogen is believed to stimulate breast cancer in some women.

However, the side effects of the drug include:

  • A slightly increased risk of uterine cancer
  • Hot flushes
  • A rise in the levels of triglycerides, one of the elements of blood cholesterol.

The drug has also been associated with weight gain and depression.

Dr Decensi, writing in the Journal of Clinical Oncology, said: "Despite the universal use of this drug for more than 20 years, its minimal active dose has never been established."

More tests will be needed. One thing doctors will want to see is if the lower dose reduces the risk of uterine cancer.

In a second report in the journal, a team at the University of Pittsburgh and the University of California at Los Angeles said women taking tamoxifen to prevent breast cancer only suffer some of the bad side effects.

The 11,000 women taking the drug had vaginal discharge, hot flushes and some of the sexual dysfunction that has been reported but not weight gain and depression.

Caution needed


[ image: Professor Gordon McVie urged caution]
Professor Gordon McVie urged caution
Professor Gordon McVie, director general of the Cancer Research Campaign, said much more research was needed before it could be firmly established that such low levels of tamoxifen were effective.

But he said research had suggested that doses of 40mg of the drug could be effective administered weekly, rather than daily.

"Lower doses are worthy of evaluation," he said.

"Tamoxifen does hang around in the blood for a long time compared to average drugs, so it might be that you do not need so much of it."

Professor McVie said that standard doses of the drug were set during clinical research 30 years ago when measurement techniques were not very sensitive.

He said tests were already under way on second generation tamoxifen drugs, raloxifene and toremifene, which appeared not to increase the risk of uterine cancer.



Advanced options | Search tips




Back to top | BBC News Home | BBC Homepage | ©


Health Contents

Background Briefings
Medical notes

Relevant Stories

13 Sep 99 | Health
Doctors clash over breast cancer drug

16 Feb 99 | Health
Cancer risk from Tamoxifen

22 Dec 98 | Health
Scientists predict drugs breakthrough

29 Oct 98 | Health
Cancer drug for healthy women

23 Sep 98 | Medical notes
Breast cancer factfile

02 Sep 98 | Health
US backs Tamoxifen as cancer prevention treatment

07 Aug 98 | Health
Tamoxifen could be first cancer prevention treatment

10 Jul 98 | Health
Doubt cast on breast cancer wonder drug





Internet Links


Breakthrough Breast Cancer

Cancer Research Campaign

Breast Cancer Campaign


The BBC is not responsible for the content of external internet sites.




In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99